Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, ca...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Elsevier España
2021-10-01
|
| Series: | Neurología |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0213485321000566 |
| _version_ | 1818648877691043840 |
|---|---|
| author | E. Caronna V. José Gallardo A. Alpuente M. Torres-Ferrus N.M. Sánchez-Mateo J. Viguera-Romero A.C. López-Veloso A. López-Bravo A.B. Gago-Veiga P. Irimia Sieira J. Porta-Etessam S. Santos-Lasaosa P. Pozo-Rosich |
| author_facet | E. Caronna V. José Gallardo A. Alpuente M. Torres-Ferrus N.M. Sánchez-Mateo J. Viguera-Romero A.C. López-Veloso A. López-Bravo A.B. Gago-Veiga P. Irimia Sieira J. Porta-Etessam S. Santos-Lasaosa P. Pozo-Rosich |
| author_sort | E. Caronna |
| collection | DOAJ |
| description | Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19. Resumen: Antecedentes y objetivo: El péptido relacionado con el gen de la calcitonina (CGRP, por sus siglas en inglés), es un neuropéptido involucrado en la fisiopatología de la migraña, que también es conocido por participar en la regulación del sistema respiratorio y en algunas enfermedades inmunológicas como la sepsis. Hemos analizado el impacto del uso de los antagonistas de CGRP en pacientes con migraña durante la pandemia de COVID-19, causada por el coronavirus SARS-CoV-2. Métodos: Estudio transversal multicéntrico desarrollado entre mayo y noviembre de 2020, en el que la Sociedad Española de Neurología distribuyó a nivel nacional una encuesta de la que recogimos datos sobre la presencia, las características y la gravedad de síntomas de COVID-19, entre los que se encontraba la cefalea, en pacientes con migraña tratados con anticuerpos monoclonales (AcM) anti-CGRP, y los comparamos con los de pacientes con migraña que no recibían dicho tratamiento. También realizamos un subanálisis de los pacientes con síntomas de COVID-19. Resultados: Identificamos 300 pacientes con migraña: 51,7% (155/300) recibían AcM anti-CGRP; el 87,3% eran mujeres (262/300) y la edad media (desviación estándar) de la muestra fue de 47,1 (11,6) años. Un total de 41 pacientes (13,7%) cumplían los criterios diagnósticos de COVID-19, sin diferencias estadísticamente significativas entre los pacientes que recibían tratamiento con AcM anti-CGRP y los que no (16,1% y 11,0%, respectivamente; p = 0,320). De los pacientes con COVID-19, el 48,8% (20/41) acudieron a urgencias y el 12,2% (5/41) fueron hospitalizados. Igualmente, no se detectaron diferencias clínicas entre los pacientes que recibían dicho tratamiento y los que no. Conclusión: El tratamiento con AcM anti-CGRP parece un recurso seguro en la práctica clínica, y no se asocia a un mayor riesgo de COVID-19. |
| first_indexed | 2024-12-17T01:25:25Z |
| format | Article |
| id | doaj.art-e3d8d2367af04868bf2eaf8f7ca265b7 |
| institution | Directory Open Access Journal |
| issn | 0213-4853 |
| language | Spanish |
| last_indexed | 2024-12-17T01:25:25Z |
| publishDate | 2021-10-01 |
| publisher | Elsevier España |
| record_format | Article |
| series | Neurología |
| spelling | doaj.art-e3d8d2367af04868bf2eaf8f7ca265b72022-12-21T22:08:42ZspaElsevier EspañaNeurología0213-48532021-10-01368611617Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implicationsE. Caronna0V. José Gallardo1A. Alpuente2M. Torres-Ferrus3N.M. Sánchez-Mateo4J. Viguera-Romero5A.C. López-Veloso6A. López-Bravo7A.B. Gago-Veiga8P. Irimia Sieira9J. Porta-Etessam10S. Santos-Lasaosa11P. Pozo-Rosich12Headache Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainHeadache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainHeadache Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainHeadache Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainHeadache Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainHeadache Unit, Neuroscience Department, Hospital Universitario Virgen Macarena, Sevilla, SpainNeurology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, SpainNeurology Department, Hospital Reina Sofia, Tudela, SpainHeadache Unit, Neurology Department, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria de La Princesa, Madrid, SpainNeurology Department, Clinica Universidad de Navarra, Pamplona, SpainDepartment of Neurology, Institute of Neurosciences, Hospital Clínico San Carlos, IdISSC, Universidad Complutense de Madrid, Madrid, SpainHeadache Unit, Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, SpainHeadache Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Corresponding author.Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19. Resumen: Antecedentes y objetivo: El péptido relacionado con el gen de la calcitonina (CGRP, por sus siglas en inglés), es un neuropéptido involucrado en la fisiopatología de la migraña, que también es conocido por participar en la regulación del sistema respiratorio y en algunas enfermedades inmunológicas como la sepsis. Hemos analizado el impacto del uso de los antagonistas de CGRP en pacientes con migraña durante la pandemia de COVID-19, causada por el coronavirus SARS-CoV-2. Métodos: Estudio transversal multicéntrico desarrollado entre mayo y noviembre de 2020, en el que la Sociedad Española de Neurología distribuyó a nivel nacional una encuesta de la que recogimos datos sobre la presencia, las características y la gravedad de síntomas de COVID-19, entre los que se encontraba la cefalea, en pacientes con migraña tratados con anticuerpos monoclonales (AcM) anti-CGRP, y los comparamos con los de pacientes con migraña que no recibían dicho tratamiento. También realizamos un subanálisis de los pacientes con síntomas de COVID-19. Resultados: Identificamos 300 pacientes con migraña: 51,7% (155/300) recibían AcM anti-CGRP; el 87,3% eran mujeres (262/300) y la edad media (desviación estándar) de la muestra fue de 47,1 (11,6) años. Un total de 41 pacientes (13,7%) cumplían los criterios diagnósticos de COVID-19, sin diferencias estadísticamente significativas entre los pacientes que recibían tratamiento con AcM anti-CGRP y los que no (16,1% y 11,0%, respectivamente; p = 0,320). De los pacientes con COVID-19, el 48,8% (20/41) acudieron a urgencias y el 12,2% (5/41) fueron hospitalizados. Igualmente, no se detectaron diferencias clínicas entre los pacientes que recibían dicho tratamiento y los que no. Conclusión: El tratamiento con AcM anti-CGRP parece un recurso seguro en la práctica clínica, y no se asocia a un mayor riesgo de COVID-19.http://www.sciencedirect.com/science/article/pii/S0213485321000566MigrañaCGRPCOVID-19Anticuerpos monoclonalesSARS-CoV-2 |
| spellingShingle | E. Caronna V. José Gallardo A. Alpuente M. Torres-Ferrus N.M. Sánchez-Mateo J. Viguera-Romero A.C. López-Veloso A. López-Bravo A.B. Gago-Veiga P. Irimia Sieira J. Porta-Etessam S. Santos-Lasaosa P. Pozo-Rosich Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications Neurología Migraña CGRP COVID-19 Anticuerpos monoclonales SARS-CoV-2 |
| title | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications |
| title_full | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications |
| title_fullStr | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications |
| title_full_unstemmed | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications |
| title_short | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications |
| title_sort | safety of anti cgrp monoclonal antibodies in patients with migraine during the covid 19 pandemic present and future implications |
| topic | Migraña CGRP COVID-19 Anticuerpos monoclonales SARS-CoV-2 |
| url | http://www.sciencedirect.com/science/article/pii/S0213485321000566 |
| work_keys_str_mv | AT ecaronna safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT vjosegallardo safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT aalpuente safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT mtorresferrus safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT nmsanchezmateo safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT jvigueraromero safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT aclopezveloso safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT alopezbravo safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT abgagoveiga safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT pirimiasieira safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT jportaetessam safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT ssantoslasaosa safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications AT ppozorosich safetyofanticgrpmonoclonalantibodiesinpatientswithmigraineduringthecovid19pandemicpresentandfutureimplications |